In this 52-week , double-blind , placebo-controlled ( up to Week 20 ) study ( NCT00928512 ) , patients responding inadequately to disease-modifying antirheumatic drugs ( DMARD ) or biologics were randomized to receive monthly subcutaneous injections of secukinumab ( 25 , 75 , 150 , or 300 mg ) , or placebo .